Building on these findings, a first-in-human Phase I/II clinical trial (NCT05092451) is currently recruiting, which aims to evaluate the safety and preliminary efficacy of allogeneic CB-derived CD70-directed CAR-NK cells in patients with relapsed or refractory MM. The gene discussed is CD70; the disease is Miyoshi myopathy.